Tocilizumab in patients infected by SARS-CoV2.
作者信息
Sancho Milagros, Muñiz Javier, Cardinal-Fernández Pablo
机构信息
Unidad de Cuidados Intensivos, Hospital Universitario Gregorio Marañón, Madrid, Spain.
Departamento de Ciencias de la Salud, Universidad de A Coruña, Spain.
出版信息
Med Clin (Engl Ed). 2021 Apr 23;156(8):402-406. doi: 10.1016/j.medcle.2020.12.010. Epub 2021 Mar 19.
Abstract
摘要
相似文献
1
Tocilizumab in patients infected by SARS-CoV2.托珠单抗用于感染新型冠状病毒的患者。
Med Clin (Engl Ed). 2021 Apr 23;156(8):402-406. doi: 10.1016/j.medcle.2020.12.010. Epub 2021 Mar 19.
2
A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.一项旨在评估托珠单抗治疗重症 COVID-19 肺炎患者的疗效和安全性的前瞻性、随机、双盲、安慰剂对照试验（TOC-COVID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):470. doi: 10.1186/s13063-020-04447-3.
3
Tocilizumab: From Rheumatic Diseases to COVID-19.托珠单抗：从风湿性疾病到 COVID-19。
Curr Pharm Des. 2021;27(13):1597-1607. doi: 10.2174/1381612827666210311141512.
4
Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature.用于严重SARS-CoV2感染管理的免疫调节。文献综述与最新进展
Biochem Biophys Res Commun. 2021 Jan 29;538:151-155. doi: 10.1016/j.bbrc.2020.11.084. Epub 2020 Nov 28.
5
Host-virus chimeric events in SARS-CoV2 infected cells are infrequent and artifactual.在感染新冠病毒（SARS-CoV2）的细胞中，宿主-病毒嵌合事件并不常见且属于人为现象。
bioRxiv. 2021 Feb 17:2021.02.17.431704. doi: 10.1101/2021.02.17.431704.
6
SARS-CoV2 Infection During Pregnancy Causes Persistent Immune Abnormalities in Women Without Affecting the Newborns.SARS-CoV2 感染在妊娠期间引起女性持续的免疫异常而不影响新生儿。
Front Immunol. 2022 Jul 14;13:947549. doi: 10.3389/fimmu.2022.947549. eCollection 2022.
7
Severe acute myopathy following SARS-CoV-2 infection: a case report and review of recent literature.新型冠状病毒2型感染后严重急性肌病：一例病例报告及近期文献综述
Skelet Muscle. 2021 Apr 21;11(1):10. doi: 10.1186/s13395-021-00266-5.
8
Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study.血清中犬尿氨酸/色氨酸比值升高与 SARS-CoV2 感染患者相关：一项观察性队列研究。
Biochim Biophys Acta Mol Basis Dis. 2021 Mar 1;1867(3):166042. doi: 10.1016/j.bbadis.2020.166042. Epub 2020 Dec 16.
9
[Symptoms of SARS-CoV-2 infections in children of day care age].[日托年龄段儿童的新冠病毒感染症状]
Monatsschr Kinderheilkd. 2022;170(12):1113-1121. doi: 10.1007/s00112-022-01640-3. Epub 2022 Nov 9.
10
Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis.托珠单抗治疗的重症新型冠状病毒肺炎患者延迟性炎症减轻与死亡率相关：一项回顾性匹配队列分析
Innate Immun. 2022 Jan;28(1):3-10. doi: 10.1177/17534259211064602. Epub 2022 Jan 28.
引用本文的文献
1
Epidemiology of the COVID-19 pneumonia in a group of hospitals from Madrid-Spain during the full period of the State of Alarm HM cohort.西班牙马德里一组医院在国家警报HM队列整个期间的COVID-19肺炎流行病学。
Rev Esp Quimioter. 2025 Mar 3;38(2):97-107. doi: 10.37201/req/110.2024. Epub 2025 Feb 14.
本文引用的文献
1
Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.在一项随机对照试验中，使用托珠单抗治疗的 2019 年冠状病毒病患者的预后和预测生物标志物。
Crit Care Med. 2022 Mar 1;50(3):398-409. doi: 10.1097/CCM.0000000000005229.
2
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.托珠单抗治疗重症 COVID-19 肺炎住院患者。
N Engl J Med. 2021 Apr 22;384(16):1503-1516. doi: 10.1056/NEJMoa2028700. Epub 2021 Feb 25.
3
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.托珠单抗对重症或危重症 2019 冠状病毒病患者 15 天临床结局的影响：随机对照试验。
BMJ. 2021 Jan 20;372:n84. doi: 10.1136/bmj.n84.
4
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.托珠单抗治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
5
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.托珠单抗对比常规治疗用于 COVID-19 成人患者伴中重度肺炎的随机临床试验
JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820.
6
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.托珠单抗与标准治疗对 COVID-19 肺炎住院患者临床恶化的影响：一项随机临床试验。
JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615.
7
COVACTA trial raises questions about tocilizumab's benefit in COVID-19.COVACTA试验引发了关于托珠单抗在新冠病毒肺炎中疗效的质疑。
Lancet Rheumatol. 2020 Oct;2(10):e592. doi: 10.1016/S2665-9913(20)30313-1. Epub 2020 Sep 9.
8
Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis.新型冠状病毒肺炎诊断和预后的关键实验室参数：一项更新的荟萃分析。
Med Clin (Engl Ed). 2020 Aug 28;155(4):143-151. doi: 10.1016/j.medcle.2020.05.004. Epub 2020 Aug 22.
9
Efficacy of tocilizumab treatment in severely ill COVID-19 patients.托珠单抗治疗重症 COVID-19 患者的疗效。
Crit Care. 2020 Aug 27;24(1):524. doi: 10.1186/s13054-020-03224-7.
10
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study.重症监护病房中新冠肺炎患者使用托珠单抗的多中心观察性研究。
Lancet Rheumatol. 2020 Oct;2(10):e603-e612. doi: 10.1016/S2665-9913(20)30277-0. Epub 2020 Aug 14.
Zotero 插件